Novonesis (Novozymes) B (CHIX:NSISBC) Piotroski F-Score: N/A (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NSISBC Novonesis (Novozymes) B CHIX:NSISBC
76 GF Score
Price kr425.45
GF Value kr428.62
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novonesis (Novozymes) B has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Novonesis (Novozymes) B's Piotroski F-Score or its related term are showing as below:

During the past 13 years, the highest Piotroski F-Score of Novonesis (Novozymes) B was 9. The lowest was 4. And the median was 6.

Novonesis (Novozymes) B  (CHIX:NSISBc) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Novonesis (Novozymes) B Piotroski F-Score Related Terms


Novonesis (Novozymes) B Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Piotroski F-Score Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 5.00 6.00 5.00

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 6.00 N/A 5.00 N/A

CHIX:NSISBC vs LIN, SHW, ECL: Piotroski F-Score Comparison

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B Piotroski F-Score vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Piotroski F-Score falls into.


CHIX:NSISBC
76GF Score
Novonesis (Novozymes) B CHIX:NSISBC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 1020.556 + 1029.979 + 917.175 + 1488.14 = kr4,456 Mil.
Cash Flow from Operations was 2388.012 + 3484.015 + 2451.277 + 1248.961 = kr9,572 Mil.
Revenue was 7598.221 + 7948.004 + 7443.458 + 8366.023 = kr31,356 Mil.
Gross Profit was 4062.083 + 4059.46 + 4173.595 + 4743.961 = kr17,039 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(112308.67 + 122355.611 + 121676.33 + 122109.016 + 123500.684) / 5 = kr120390.0622 Mil.
Total Assets at the begining of this year (Mar25) was kr112,309 Mil.
Long-Term Debt & Capital Lease Obligation was kr21,849 Mil.
Total Current Assets was kr15,290 Mil.
Total Current Liabilities was kr9,137 Mil.
Net Income was 228.383 + 1160.924 + 642.853 + 1387.319 = kr3,419 Mil.

Revenue was 7300.805 + 7608.265 + 7318.983 + 8037.498 = kr30,266 Mil.
Gross Profit was 2995.106 + 4082.993 + 3690.814 + 4432.707 = kr15,202 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(0 + 113834.934 + 0 + 113324.17 + 112308.67) / 5 = kr113155.92466667 Mil.
Total Assets at the begining of last year (Mar24) was kr0 Mil.
Long-Term Debt & Capital Lease Obligation was kr9,466 Mil.
Total Current Assets was kr14,514 Mil.
Total Current Liabilities was kr8,728 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novonesis (Novozymes) B's current Net Income (TTM) was 4,456. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novonesis (Novozymes) B's current Cash Flow from Operations (TTM) was 9,572. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=4455.85/112308.67
=0.03967503

ROA (Last Year)=Net Income/Total Assets (Mar24)
=3419.479/0
=

Novonesis (Novozymes) B's return on assets of this year was 0.03967503. Novonesis (Novozymes) B's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Novonesis (Novozymes) B's current Net Income (TTM) was 4,456. Novonesis (Novozymes) B's current Cash Flow from Operations (TTM) was 9,572. ==> 9,572 > 4,456 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=21848.977/120390.0622
=0.18148489

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=9465.84/113155.92466667
=0.08365307

Novonesis (Novozymes) B's gearing of this year was 0.18148489. Novonesis (Novozymes) B's gearing of last year was 0.08365307. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=15290.248/9136.627
=1.67351124

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=14513.89/8728.174
=1.66287817

Novonesis (Novozymes) B's current ratio of this year was 1.67351124. Novonesis (Novozymes) B's current ratio of last year was 1.66287817. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Novonesis (Novozymes) B's number of shares in issue this year was 467.2. Novonesis (Novozymes) B's number of shares in issue last year was 468.1. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=17039.099/31355.706
=0.54341302

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15201.62/30265.551
=0.50227468

Novonesis (Novozymes) B's gross margin of this year was 0.54341302. Novonesis (Novozymes) B's gross margin of last year was 0.50227468. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=31355.706/112308.67
=0.27919221

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=30265.551/0
=

Novonesis (Novozymes) B's asset turnover of this year was 0.27919221. Novonesis (Novozymes) B's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novonesis (Novozymes) B has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Is Novonesis (Novozymes) B (CHIX:NSISBC) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of kr425.45 is trading 0.7% below its estimated GF Value™ of kr428.62. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for CHIX:NSISBC:

  • Piotroski F-Score: N/A
  • GF Value™: kr428.62 vs. price of kr425.45 (0.7% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the CHIX:NSISBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
76GF Score

Get the complete analysis for CHIX:NSISBC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr425.45
Price
kr428.62
GF Value